Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | BHMT | Q93088 | 2/20 | 0.37 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30703416 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL6195247 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL6423820 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL30703408 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL6193670 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL6195143 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL6476938 | 1.00 | NOS2 (0.44) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL7079015 | 0.98 | NOS2 (0.43) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL7083750 | 0.98 | NOS2 (0.43) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL7082607 | 0.98 | NOS2 (0.43) | NOS2NOS1NOS3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505972-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1506040-A2 | SELECTIVE INOS INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | MANNING PAMELA T (US) | 2004-05-06 | — | — | US | claimed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | claimed |
| WO-2003097163-A2 | USING A SELECTIVE INOS INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES AND CONDITIONS | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| WO-2003097050-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| EP-1084104-B1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-07-16 | — | — | EP | claimed |
| US-6495606-B1 | ADMINISTERING S-((R)-2-(1-IMINOETHYLAMINO)PROPYL)-L-CYSTEINE | SMITHKLINE BEECHAM CORPORATION | 2002-12-17 | — | — | US | claimed |
| US-6355689-B1 | ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2002-03-12 | — | — | US | claimed |
| EP-1084104-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062875-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-12-09 | — | — | WO | claimed |
| US-12163161-B2 | In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2024-12-10 | — | — | US | disclosed |
| EP-3427061-B1 | USE OF SELECTIVE INOS INHIBITORS FOR TREATING THORACIC AORTIC ANEURYSM | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III F S P (ES) | 2023-12-06 | — | — | EP | disclosed |
| US-20210363501-A1 | IN VITRO METHOD FOR IDENTIFYING THORACIC AORTIC ANEURYSMS (TAA) IN A SUBJECT | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III F S P (ES) | 2021-11-25 | — | — | US | disclosed |
| US-10907135-B2 | In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2021-02-02 | — | — | US | disclosed |
| EP-1084104-B1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-6495606-B1 | ADMINISTERING S-((R)-2-(1-IMINOETHYLAMINO)PROPYL)-L-CYSTEINE | SMITHKLINE BEECHAM CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6355689-B1 | ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2002-03-12 | — | — | US | disclosed |
| EP-1084104-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062875-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | NOS2, NOS1, PDE3A | NOS2 1/4885NOS1 2/4885NOS3 7/4885 |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.